Luminex, EMD Millipore Extend Distribution Agreement | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Tuesday it has extended its global supply and distribution agreement with EMD Millipore.

The deal with EMD Millipore, the Life Science division of Merck KGaA, is anticipated to further the development of protein assays by EMD Millipore for Luminex's xMAP platform, the Austin, Texas-based firm said. EMD Millipore also will continue to offer all of Luminex's xMAP systems, including the Magpix, Luminex 100/200, and Flexmap 3D.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.